Cowen downgraded Cano Health from Outperform to Market Perform and set a new price target of $3.00 from $10.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2023 | Buy → Hold | Jefferies | |
| 8/11/2023 | $4.00 → $0.80 | Buy → Neutral | Citigroup |
| 1/6/2023 | $12.00 → $1.25 | Buy → Neutral | UBS |
| 1/5/2023 | Outperform → Peer Perform | Wolfe Research | |
| 12/13/2022 | $1.50 | Underperform | BofA Securities |
| 11/10/2022 | $10.00 → $3.00 | Outperform → Market Perform | Cowen |
| 11/10/2022 | Outperform → Mkt Perform | Raymond James | |
| 10/27/2022 | $10.00 → $5.00 | Outperform → Neutral | Credit Suisse |
MIAMI, Aug. 9, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company") (NYSE:CANO), announced today that it has rescheduled its second quarter 2023 earnings release and conference call to tomorrow afternoon. A press release with the business and financial results will be issued on Thursday, August 10, 2023 after the market closes, and the Company will host a conference call at 5:00 PM Eastern Time the same day to review its business and financial results. The earnings release and call were previously scheduled for today after the market close. To access the li
MIAMI, July 25, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company") (NYSE:CANO), a leading value-based primary care provider and population health company, will release its financial results for the second quarter 2023 after the market closes on Wednesday, August 9, 2023, and will host a conference call at 5:00 PM Eastern Time the same day to review its business and financial results. To access the live call and webcast, please dial (888) 660-6359 for U.S. participants, or (929) 203-0867 for international participants, referencing the Cano Health Second Qu
Raises guidance for full year 2023 membership and total revenue; maintains outlook for medical cost ratio and Adjusted EBITDA Pursuing divestiture of certain non-core assets to strengthen its focus on high-performing Medicare Advantage business MIAMI, May 9, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company") (NYSE:CANO), a leading value-based primary care provider and population health company, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Total membership of 388,667 including 207,420 Med
SC 13G/A - Cano Health, Inc. (0001800682) (Subject)
SC 13D/A - Cano Health, Inc. (0001800682) (Subject)
SC 13G - Cano Health, Inc. (0001800682) (Subject)
8-K - Cano Health, Inc. (0001800682) (Filer)
8-K - Cano Health, Inc. (0001800682) (Filer)
25-NSE - Cano Health, Inc. (0001800682) (Subject)
Jefferies downgraded Cano Health from Buy to Hold
Citigroup downgraded Cano Health from Buy to Neutral and set a new price target of $0.80 from $4.00 previously
UBS downgraded Cano Health from Buy to Neutral and set a new price target of $1.25 from $12.00 previously
4 - Cano Health, Inc. (0001800682) (Issuer)
4 - Cano Health, Inc. (0001800682) (Issuer)
4 - Cano Health, Inc. (0001800682) (Issuer)
Patricia Ferrari and Carol Flaton to Enhance the Board's and Management's Ongoing Strategic, Operational and Financing Initiatives MIAMI, Dec. 18, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company") (NYSE:CANO), a leading value-based primary care provider and population health company, today announced the appointment of Patricia Ferrari and Carol Flaton to its Board of Directors. Ms. Ferrari and Ms. Flaton bring broad business experience and deep financial expertise, with proven track records of advising companies on strategies to improve operations and financial performance, as well as strengthening their capital structures.
Mr. Kent immediately joins Board of Directors, replacing Dr. Marlow Hernandez who has stepped down MIAMI, Aug. 21, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced that its Board of Directors has appointed Mark Kent as Chief Executive Officer, effective immediately. The Board also elected Mr. Kent, who has served as interim Chief Executive Officer since June 16, 2023, to Cano Health's Board of Directors. The Board also announced that Dr. Marlow Hernandez has stepped down from the Board effective immediately. Regarding Mr. Kent's appointment, the Board issued the following state
MIAMI, June 22, 2023 /PRNewswire/ -- Cano Health, Inc. ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today filed with the SEC final voting results from its Annual Stockholders' Meeting held on June 15, 2023. An aggregate of 457,462,704 shares—or 85.3% of the Company's Class A and Class B common stock outstanding as of the record date for the meeting—were represented in person or by proxy at the meeting. Cano Health's Board of Directors issued the following statement: "As previously stated, we are well aware of the significant withhold vote and we take seriously the feedback we have received from, and our duty to, our stockholders
Emergence from Chapter 11 Expected in Third Quarter of 2024 MIAMI, May 21, 2024 /PRNewswire/ -- Cano Health, Inc. (NYSE: CANO) ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced a global agreement with the Unsecured Creditors Committee representing the interests of the Company's general unsecured creditors, with the support of the Ad Hoc Lender Group. It also received approval of its Disclosure Statement by the U.S. Bankruptcy Court for the District of Delaware (the "Court"), paving the way to solicit creditor approval of its Plan of Reorganization and its expected emergence from Chapter 11 in the third quarter. Mark
MIAMI, Feb. 5, 2024 /PRNewswire/ -- Cano Health, Inc. (NYSE:CANO) ("Cano Health" or the "Company") announced today that on February 5, 2024, the New York Stock Exchange (the "NYSE") notified the Company that the NYSE had determined to (a) commence proceedings to delist the Company's Class A common stock, par value $0.01 per share ("Common Stock") and (b) immediately suspend trading in the Company's Common Stock pursuant to Section 802.01D of the NYSE Listed Company Manual after the Company filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on February 4, 2024.
Positions the Company to Advance Its Ongoing Transformation Plan Designed to Significantly Reduce Costs, Enhance Productivity, and Improve Cash Flow Receives Commitment for $150 Million in New Capital Ensures Patients Continue to Receive High-Quality Care Across Medical Centers MIAMI, Feb. 4, 2024 /PRNewswire/ -- Cano Health, Inc. (NYSE:CANO) ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced that it has entered into a Restructuring Support Agreement (the "RSA") with lenders (the "Ad Hoc Lender Group") holding approximately 86% of its secured revolving and term loan debt and 92% of its senior unsecured notes. This a
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD. 4D Molecular Therapeutics shares jumped 20.1% to $21.01 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Chenghe Acquisition Co. (NASDAQ:CHEA) gained 68.1% to $9.23 in pre-market trading after dipping around 46% on Friday. Tritium DCFC Limited (NASDAQ:DCFC) shares jumped 51.9% to $0.1990 in pre-market trading. Tritium DCFC said the company was the top-awarded fast charger manufacturer f